Immunotherapy Combo Effective in Castration-resistant Prostate Cancer Mouse Models, Study Finds

Immunotherapy Combo Effective in Castration-resistant Prostate Cancer Mouse Models, Study Finds
Combining immune checkpoint inhibitors with drugs that target a population of myeloid-derived suppressor cells (MDSCs) may offer hope for men with metastatic prostate cancer who no longer respond to androgen deprivation therapy (ADT). Researchers at Houston's University of Texas MD Anderson Cancer Center conducted the mice study, which appeared in the journal Nature. "A significant number of advanced prostate cancer patients treated with a chemical castration therapy called androgen deprivation therapy experience relapse with relentless progression to lethal metastatic, castration-resistant prostate cancer,
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *